Page last updated: 2024-09-03
tak 044 and clazosentan
tak 044 has been researched along with clazosentan in 1 studies
Compound Research Comparison
| Studies (tak 044) | Trials (tak 044) | Recent Studies (post-2010) (tak 044) | Studies (clazosentan) | Trials (clazosentan) | Recent Studies (post-2010) (clazosentan) |
|---|---|---|---|---|---|
| 105 | 8 | 2 | 94 | 33 | 61 |
Protein Interaction Comparison
| Protein | Taxonomy | tak 044 (IC50) | clazosentan (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 0.175 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0017 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Algra, A; Rinkel, GJ; Vergouwen, MD | 1 |
Reviews
1 review(s) available for tak 044 and clazosentan
| Article | Year |
|---|---|
Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.
Topics: Bosentan; Contraindications; Dioxanes; Endothelin Receptor Antagonists; Humans; Incidence; Peptides, Cyclic; Pyridines; Pyrimidines; Receptors, Endothelin; Subarachnoid Hemorrhage; Sulfonamides; Tetrazoles; Treatment Outcome; Vasospasm, Intracranial | 2012 |